Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082121 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
A Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency, sponsored by Avant Immunotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 18
- Study locations
NCT00082121: Completed Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency, sponsored by Avant Immunotherapeutics.
NCT00082121 is a Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency that has completed, run by Avant Immunotherapeutics. The registered enrollment target is 300 participants, below the 2,128-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (86% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082121, a Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency, has completed, sponsored by Avant Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.
Conditions Studied
Interventions
- DRUG TP10
Study Locations (18)
Florida
- - Gainesville
- - Orlando
- - Sarasota
Massachusetts
- - Boston
- - Springfield
Michigan
- - Detroit
- - Lansing
Wisconsin
- - Madison
- - Milwaukee
California
- - San Francisco
District of Columbia
- - Washington D.C.
Georgia
- - Atlanta
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00082121 record still lists
NCT00082121 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,128-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Myocardial Ischemia appearing as the primary indexed condition, and to 1 intervention - of which TP10 is the first listed.
NCT00082121 lists 18 locations in 13 states (Florida, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT00082121 about?
NCT00082121 is a clinical study titled "Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery". The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.
What is the current status of trial NCT00082121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2004-04. Estimated completion is 2005-12.
What conditions does trial NCT00082121 study?
This clinical trial studies the following conditions: Myocardial Ischemia, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Coronary Arteriosclerosis.
What interventions are being tested in trial NCT00082121?
The interventions under investigation include: TP10 (DRUG).
Who is sponsoring clinical trial NCT00082121?
This trial is sponsored by Avant Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00082121 being conducted?
This trial has 18 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00082121's enrollment target sits among peer trials
300 15th of 29 higher than 15 of 29 other Myocardial Ischemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACT34-CMI -- Adult Autologous CD34+ Cells
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
-
Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease
COMPLETED · Phase 2
-
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
COMPLETED · Phase 2
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia